Current research into the molecular mechanisms of HER3 has revealed its role in oncogenic signaling cascades that underpin NSCLC progression, thereby highlighting the potential of HER3 as a therapeutic target (42). This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.